Kusum Healthcare Private Limited

Kusum Healthcare Private Limited, established on March 12, 1997, is a privately held pharmaceutical company headquartered in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U65929DL1997PTC085780. As of March 31, 2024, Kusum Healthcare reported an authorized capital of ₹10.00 crore and a paid-up capital of ₹7.99 crore. The company employs approximately 726 professionals, reflecting its significant presence in the pharmaceutical sector. Kusum Healthcare specializes in the formulation and development of finished pharmaceutical products, including tablets, capsules, syrups, and injections, across various therapeutic categories. The company's official website is www.kusumhealthcare.com.

Kusum Healthcare operates manufacturing facilities in India, strategically located to serve both domestic and international markets. While specific details regarding plant locations and capacities are not publicly disclosed, the company's substantial export volume indicates robust manufacturing capabilities. The facilities are equipped to produce a diverse range of finished pharmaceutical formulations, adhering to international quality standards.

The leadership team at Kusum Healthcare comprises experienced professionals dedicated to steering the company's growth and operational excellence. Key executives include:

• Sanjeev Gupta: Director
• Badri Prasad Gupta: Director
• Deepak Mangal: Director
• Anil Tyagi: Director

These leaders bring a wealth of experience in the pharmaceutical industry, contributing to the company's strategic direction and success.

Kusum Healthcare has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has successfully navigated the regulatory landscapes of these regions, obtaining necessary approvals for its pharmaceutical products. This achievement underscores Kusum Healthcare's commitment to maintaining high-quality standards and compliance with international regulations. The company's ability to secure market access in these regions reflects its robust manufacturing processes and adherence to global pharmaceutical standards.

Kusum Healthcare has strategically expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's products have been prequalified by the World Health Organization (WHO), facilitating access to these regions. This prequalification enables Kusum Healthcare to supply essential medicines to countries with critical healthcare needs, enhancing its global reach and impact. The company's focus on emerging markets aligns with its mission to provide quality healthcare solutions worldwide.

Kusum Healthcare's geographic strategy demonstrates a balanced approach to market diversification. The company's substantial export value of $21.0 million USD, derived from 1,205 shipments across 13 products in 7 therapeutic categories, indicates a well-distributed market presence. The top three therapeutic categories—Antifungals (59.8%), Antibiotics (12.8%), and Vitamins & Supplements (10.8%)—highlight the company's strategic focus on high-demand segments. This diversification mitigates concentration risk and positions Kusum Healthcare for sustained growth in various global markets.

Kusum Healthcare has achieved significant milestones in the United States market. The company has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), ensuring compliance with stringent regulatory standards. Additionally, Kusum Healthcare has received approval for Abbreviated New Drug Applications (ANDAs), allowing it to market generic pharmaceutical products in the U.S. The company has also filed Drug Master Files (DMFs) with the FDA, providing detailed information about its manufacturing processes and quality control measures. These accomplishments reflect Kusum Healthcare's commitment to maintaining high-quality standards and regulatory compliance in the U.S. market.

Kusum Healthcare has obtained prequalification from the World Health Organization (WHO), affirming the quality, safety, and efficacy of its pharmaceutical products. This prequalification facilitates the company's entry into international markets, particularly those with stringent regulatory requirements. The company has also secured Good Manufacturing Practice (GMP) certifications from the European Union (EU), demonstrating adherence to international manufacturing standards. These certifications underscore Kusum Healthcare's dedication to producing high-quality pharmaceutical products for global markets.

In India, Kusum Healthcare holds manufacturing licenses issued by the Central Drugs Standard Control Organisation (CDSCO), authorizing it to produce pharmaceutical products for domestic and export markets. The company has obtained approvals from state drug controllers, ensuring compliance with regional regulatory requirements. Kusum Healthcare has also secured export No Objection Certificates (NOCs), facilitating the export of its products to various international markets. These regulatory approvals reflect the company's commitment to maintaining high-quality standards and adhering to Indian pharmaceutical regulations.

As of March 28, 2026, there are no publicly available records indicating that Kusum Healthcare has received Form 483 observations, warning letters, or import alerts from regulatory authorities. This absence suggests that the company maintains a strong compliance record and adheres to regulatory standards in its operations.

Kusum Healthcare operates in a competitive pharmaceutical market, facing competition from both domestic and international companies. While specific market share data is not publicly disclosed, the company's substantial export value of $21.0 million USD and its presence in multiple therapeutic categories indicate a significant market position. The company's focus on high-demand segments such as Antifungals, Antibiotics, and Vitamins & Supplements positions it favorably against competitors in these areas. Kusum Healthcare's ability to secure regulatory approvals in diverse markets further enhances its competitive standing.

Kusum Healthcare's key differentiators include its comprehensive product portfolio, encompassing 13 products across 7 therapeutic categories, with a concentration in high-demand segments. The company's leadership in markets for Ketoconazole, Biotin, and Pyrantel underscores its expertise in these areas. Additionally, Kusum Healthcare's commitment to quality is evidenced by its WHO prequalification and EU GMP certifications, ensuring adherence to international manufacturing standards. The company's strategic geographic diversification and focus on emerging markets further distinguish it in the global pharmaceutical landscape.

Kusum Healthcare's current strategic direction emphasizes the production of generic pharmaceutical products, leveraging its manufacturing capabilities and regulatory approvals to serve both domestic and international markets. The company's focus on high-demand therapeutic categories positions it to meet global healthcare needs effectively. Looking ahead, Kusum Healthcare may explore opportunities in specialty pharmaceuticals, biosimilars, and contract development and manufacturing organizations (CDMO) to further diversify its portfolio and enhance its market presence.

Kusum Healthcare demonstrates a strong track record as a pharmaceutical exporter, with a total export value of $21.0 million USD and 1,205 shipments across 13 products in 7 therapeutic categories. The company's portfolio concentration, with the top 5 products accounting for 71.2% of exports, indicates a focused approach to high-demand segments. The absence of publicly available records indicating regulatory non-compliance further underscores the company's reliability as a supplier. Kusum Healthcare's adherence to international quality standards, as evidenced by its WHO prequalification and EU GMP certifications, enhances its reputation for consistency and quality.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Facility Registration: Confirm the registration status of Kusum Healthcare's manufacturing facilities with the U.S. Food and Drug Administration (FDA).

• WHO Prequalification: Verify the World Health Organization's prequalification status of Kusum Healthcare's products.

• EU GMP Certification: Ensure that Kusum Healthcare holds Good Manufacturing Practice (GMP) certification from the European Union.

• ISO Certification: Check for ISO certifications related to quality management systems.

These certifications can typically be verified through the respective regulatory bodies' official websites or by contacting Kusum Healthcare directly.

Importers should undertake the following steps to ensure a thorough evaluation of Kusum Healthcare:

• Verify Regulatory Approvals: Confirm that Kusum Healthcare's products are approved by relevant regulatory authorities in target markets.

• Assess Manufacturing Facilities: Evaluate the compliance of Kusum Healthcare's manufacturing facilities with international quality standards.

• Review Financial Stability: Analyze Kusum Healthcare's financial statements to assess its economic health and capacity to fulfill orders.

• Check References: Obtain feedback from existing clients or partners to gauge Kusum Healthcare's reliability and service quality.

• Monitor